Immuno-Oncology | Specialty

Choosing Therapy for Newly Diagnosed NonDriver NSCLC

February 26th 2019

Driver Mutations Trump PD-L1 Expression in Lung Adenocarcinoma

February 26th 2019

Biomarker Testing in Stage III NSCLC

February 26th 2019

Imaging Schedule Following CRT in Locally Advanced NSCLC

February 26th 2019

The Role of Surgery in NSCLC Following PACIFIC Trial

February 26th 2019

Impact of PACIFIC Trial on Locally Advanced NSCLC

February 26th 2019

Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

February 25th 2019

Two doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results from a subgroup analysis of a large randomized, placebo-controlled trial showed.1

Dr. Socinski on Current State of Treatment in NSCLC

February 22nd 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses the current state of treatment for patients with non–small cell lung cancer.

Dr. Grivas on Unmet Needs in Advanced Urothelial Cancer

February 20th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses unmet needs in the treatment of patients with advanced urothelial cancer.

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC

February 19th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent pembrolizumab in the treatment of patients with advanced renal cell carcinoma.

Dr. Choueiri Discusses Avelumab/Axitinib Data in RCC

February 16th 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses avelumab/axitinib data in renal cell carcinoma.

FDA Grants Pembrolizumab/Axitinib Combo Priority Review for Frontline RCC

February 15th 2019

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of pembrolizumab and axitinib as a frontline treatment for patients with advanced renal cell carcinoma.

Dr. Brahmer on Immunotherapy Beyond PD-1/L1 in NSCLC

February 13th 2019

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the potential for immunotherapy beyond PD-1 and PD-L1 checkpoints in non–small cell lung cancer.

FDA Grants Avelumab/Axitinib Combo Priority Review for RCC

February 12th 2019

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of avelumab and axitinib as a treatment for patients with advanced renal cell carcinoma.

Immuno-Oncology Expert Highlights How Steroid Dosage Influences Response

February 9th 2019

Different patterns of response are associated with the dosages of immunosuppressants used to manage the adverse effects of immunotherapies.

Dr. Subramanian on the Future of Immunotherapy in NSCLC

February 9th 2019

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at St. Luke’s Cancer Institute, discusses the future of immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Grivas on Checkpoint Inhibitors in Localized Bladder Cancer

February 7th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the role of checkpoint inhibitors in the treatment of patients with localized bladder cancer.

EU Panel Recommends Pembrolizumab/Chemo Combo in Squamous NSCLC

February 4th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for first-line treatment with pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel in patients with metastatic squamous non–small cell lung cancer.

EU Panel Backs Frontline Atezolizumab Regimen in NSCLC

February 2nd 2019

The European Medicine’s Agency Committee for Medicinal Products for Human Use has recommended approval for the frontline combination of atezolizumab, bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer.

Combos and Biomarkers Will Shape the Future of Bladder Cancer Immunotherapy

February 1st 2019

Although multiple checkpoint inhibitors have been introduced into the bladder cancer treatment paradigm during the past several years, their use in the malignancy remains an unfolding story.